Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study.
Axel Ursenbach, Vincent Max, Marine Maurel...
https://pubmed.ncbi.nlm.nih.gov/32791523/Actively Recruiting
Led by DatAids · Updated on 2026-02-20
30000
Participants Needed
39
Research Sites
N/A
Total Duration
The Dataids cohort is a large, ongoing observational study following over 30,000 HIV-infected patients receiving care at more than 15 HIV centers across France. The study aims to monitor clinical practice, changes in the course of HIV infection and related co-infections or co-morbidities, and assess factors influencing the clinical, immunological, and virological outcomes of HIV. It also evaluates the effectiveness of antiretroviral therapy ART and outcomes related to hepatitis C virus HCV treatment. Patients enrolled in the cohort are followed during routine outpatient visits, regardless of their CD4 cell count, HIV viral load, or ART status. Data collected annually include demographic information, immunological and virological measures, serological tests for hepatitis B, hepatitis C, and syphilis, as well as laboratory, therapeutic, and clinical data. This long-term study has been enrolling patients since 2010 and continues to collect data prospectively. Participants provide data through their scheduled clinic visits, and researchers track outcomes such as the proportion of patients with undetectable HIV viral load, ART usage patterns, HCV treatment uptake and success, CD4 cell counts, and incidence of HIV-related events. The main outcome measured is the proportion of treated patients with HIV plasma viral load below 50 copiesmL, averaged over six months. The study extends through 2030, with ongoing annual monitoring and data collection as part of routine care.
CONDITIONS
Quality of Care in French HIV Infected Patients
P
Pascal Pugliese, MD
S
Solène SECHER
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
DatAids
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Ongoing through study completion, up to 10 years
Participants who undergo routine care are observed. Demographic, immunological, virological, serological, laboratory, therapeutic, and clinical data are collected annually as part of routine clinical visits.
Annual visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Axel Ursenbach, Vincent Max, Marine Maurel...
https://pubmed.ncbi.nlm.nih.gov/32791523/Pierre Gantner, Laurent Cotte, Clotilde Allavena...
https://pubmed.ncbi.nlm.nih.gov/30998789/Lise Cuzin, Clotilde Allavena, Laurent Cotte...
https://pubmed.ncbi.nlm.nih.gov/33704444/Maxime Hentzien, Moustapha Dramé, Cyrille Delpierre...
https://pubmed.ncbi.nlm.nih.gov/30782744/Adrien Le Guillou, Pascal Pugliese, François Raffi...
https://pubmed.ncbi.nlm.nih.gov/31612225/Laurent Cotte, Laurent Hocqueloux, Maeva Lefebvre...
https://pubmed.ncbi.nlm.nih.gov/33400777/Victor Virlogeux, Fabien Zoulim, Pascal Pugliese...
https://pubmed.ncbi.nlm.nih.gov/29249202/Pascal Pugliese, Lise Cuzin, André Cabié...
https://pubmed.ncbi.nlm.nih.gov/19486189/Romain Palich, Maxime Hentzien, Laurent Hocqueloux...
https://pubmed.ncbi.nlm.nih.gov/37115905/DatAids
Lead Sponsor